Impact of cefazolin co-administration with vancomycin to reduce development of vancomycin-intermediate Staphylococcus aureus
Development of antimicrobial resistance during monotherapy of complicated methicillin-resistant Staphylococcus aureus bacteremia is problematic due to cross-resistance between vancomycin (VAN) and daptomycin, the only approved agents for this condition. Our objective was to demonstrate that development of resistance under conditions of suboptimal VAN (200 mg q 12 h) exposure in S. aureus can be attenuated by addition of cefazolin (CFZ).
Source: Diagnostic Microbiology and Infectious Disease - Category: Microbiology Authors: Nivedita B. Singh, Juwon Yim, Seyedehameneh Jahanbakhsh, George Sakoulas, Michael J. Rybak Source Type: research
More News: Antimicrobial Resistance | Cubicin | Infectious Diseases | Microbiology | MRSA | Staphylococcus Aureus